{"_meta":{"current_page":1,"per_page":25,"total_pages":12,"total_count":296,"links":{"next":"https://civic.genome.wustl.edu/api/genes?count=25\u0026page=2","previous":null}},"records":[{"id":1,"name":"ALK","entrez_id":238,"description":"ALK amplifications, fusions and mutations have been shown to be driving events in non-small cell lung cancer. While crizontinib has demonstrated efficacy in treating the amplification, mutations in ALK have been shown to confer resistance to current tyrosine kinase inhibitors. Second-generation TKI's have seen varied success in treating these resistant cases, and the HSP90 inhibitor 17-AAG has been shown to be cytostatic in ALK-altered cell lines.","variants":[{"name":"EML4-ALK L1152R","id":307,"evidence_items":{"accepted_count":1,"rejected_count":0,"submitted_count":0}},{"name":"EML4-ALK E6;A20","id":503,"evidence_items":{"accepted_count":7,"rejected_count":0,"submitted_count":0}},{"name":"R1275Q","id":9,"evidence_items":{"accepted_count":6,"rejected_count":0,"submitted_count":2}},{"name":"ALK FUSION G1269A","id":552,"evidence_items":{"accepted_count":4,"rejected_count":0,"submitted_count":0}},{"name":"EML4-ALK T1151INST","id":173,"evidence_items":{"accepted_count":4,"rejected_count":0,"submitted_count":1}},{"name":"EML4-ALK C1156Y","id":6,"evidence_items":{"accepted_count":3,"rejected_count":0,"submitted_count":5}},{"name":"ALK FUSION G1202R","id":171,"evidence_items":{"accepted_count":6,"rejected_count":0,"submitted_count":2}},{"name":"MUTATION","id":512,"evidence_items":{"accepted_count":1,"rejected_count":0,"submitted_count":0}},{"name":"EML4-ALK S1206Y","id":172,"evidence_items":{"accepted_count":2,"rejected_count":0,"submitted_count":2}},{"name":"EML4-ALK  V1180L","id":528,"evidence_items":{"accepted_count":5,"rejected_count":0,"submitted_count":0}},{"name":"EML4-ALK E2;A20","id":501,"evidence_items":{"accepted_count":2,"rejected_count":0,"submitted_count":0}},{"name":"NPM-ALK","id":513,"evidence_items":{"accepted_count":3,"rejected_count":1,"submitted_count":0}},{"name":"ALTERNATIVE TRANSCRIPT (ATI)","id":839,"evidence_items":{"accepted_count":1,"rejected_count":0,"submitted_count":0}},{"name":"EML4-ALK I1171S","id":589,"evidence_items":{"accepted_count":1,"rejected_count":0,"submitted_count":1}},{"name":"ALK FUSION I1171","id":527,"evidence_items":{"accepted_count":7,"rejected_count":0,"submitted_count":3}},{"name":"EML4-ALK C1156Y–L1198F","id":352,"evidence_items":{"accepted_count":2,"rejected_count":0,"submitted_count":0}},{"name":"CLTC-ALK","id":520,"evidence_items":{"accepted_count":3,"rejected_count":0,"submitted_count":0}},{"name":"EML4-ALK","id":5,"evidence_items":{"accepted_count":7,"rejected_count":0,"submitted_count":0}},{"name":"HIP1-ALK I1171N","id":588,"evidence_items":{"accepted_count":1,"rejected_count":0,"submitted_count":2}},{"name":"F1245C","id":549,"evidence_items":{"accepted_count":2,"rejected_count":0,"submitted_count":0}},{"name":"EML4-ALK E20;A20","id":500,"evidence_items":{"accepted_count":4,"rejected_count":0,"submitted_count":0}},{"name":"F1174L","id":8,"evidence_items":{"accepted_count":9,"rejected_count":0,"submitted_count":3}},{"name":"ALK FUSION F1245C","id":551,"evidence_items":{"accepted_count":3,"rejected_count":0,"submitted_count":0}},{"name":"RANBP2-ALK","id":514,"evidence_items":{"accepted_count":1,"rejected_count":0,"submitted_count":0}},{"name":"EML4-ALK C1156Y–L1196M","id":608,"evidence_items":{"accepted_count":1,"rejected_count":0,"submitted_count":0}},{"name":"EML4-ALK G1269A","id":308,"evidence_items":{"accepted_count":2,"rejected_count":0,"submitted_count":5}},{"name":"EML4-ALK L1196M","id":7,"evidence_items":{"accepted_count":4,"rejected_count":0,"submitted_count":8}},{"name":"ALK FUSIONS","id":499,"evidence_items":{"accepted_count":23,"rejected_count":2,"submitted_count":1}},{"name":"DEL4-11","id":550,"evidence_items":{"accepted_count":1,"rejected_count":0,"submitted_count":0}},{"name":"EML4-ALK AMPLIFICATION","id":170,"evidence_items":{"accepted_count":3,"rejected_count":0,"submitted_count":0}}],"aliases":["ALK","NBLST3","CD246"],"type":"gene"},{"id":2,"name":"AKT1","entrez_id":207,"description":"AKT1, also referred to as protein kinase B, is a known oncogene. AKT activation relies on the PI3K pathway, and is recognized as a critical node in the pathway. The E17 hotspot is the most characterized of AKT1 mutations, and has been shown to result in activation of the protein. Mutations in AKT1 have also been shown to confer resistance to allosteric kinase inhibitors in vitro.","variants":[{"name":"E17K","id":4,"evidence_items":{"accepted_count":5,"rejected_count":0,"submitted_count":0}},{"name":"Q79K","id":169,"evidence_items":{"accepted_count":2,"rejected_count":0,"submitted_count":0}}],"aliases":["PKB-ALPHA","CWS6","RAC","AKT1","RAC-ALPHA","AKT","PKB","PRKBA"],"type":"gene"},{"id":3,"name":"ARAF","entrez_id":369,"description":"ARAF has recently become increasingly considered for its oncogenic potential. Its potential as a target for informing clinical action was demonstrated by a single case of advanced lung adenocarcinoma harboring an S214C mutation that, when treated with sorafenib, acheived near-complete clinical remission. This finding has brought new focus on ARAF as a marker that should be assayed for in cancer treatment.","variants":[{"name":"S214C","id":10,"evidence_items":{"accepted_count":3,"rejected_count":0,"submitted_count":0}},{"name":"S490T","id":825,"evidence_items":{"accepted_count":1,"rejected_count":0,"submitted_count":0}}],"aliases":["ARAF","PKS2","ARAF1","A-RAF","RAFA1"],"type":"gene"},{"id":4,"name":"ABL1","entrez_id":25,"description":"ABL1 is most relevant to cancer in its role in the BCR-ABL fusion protein that has become a signature of chronic myeloid leukemia (CML). Cells harboring this fusion have shown sensitivity to imatinib, greatly improving the prognostic outlook of the disease. However, additional mutations in ABL1 have been shown to confer resistance to imatinib. In these resistance cases, second-generation tyrosine kinase inhibitors such as dasatinib and nilotinib have exhibited some efficacy and are currently undergoing clinical trials for treating acquired resistance in CML.","variants":[{"name":"V299L","id":1231,"evidence_items":{"accepted_count":1,"rejected_count":0,"submitted_count":5}},{"name":"L387F","id":1232,"evidence_items":{"accepted_count":1,"rejected_count":0,"submitted_count":2}},{"name":"M351T","id":1029,"evidence_items":{"accepted_count":3,"rejected_count":0,"submitted_count":10}},{"name":"Y253H","id":1025,"evidence_items":{"accepted_count":1,"rejected_count":0,"submitted_count":10}},{"name":"BCR-ABL E255K","id":3,"evidence_items":{"accepted_count":4,"rejected_count":0,"submitted_count":11}},{"name":"BCR-ABL T334I","id":2,"evidence_items":{"accepted_count":6,"rejected_count":0,"submitted_count":23}},{"name":"Q252H","id":1024,"evidence_items":{"accepted_count":1,"rejected_count":0,"submitted_count":10}},{"name":"L248V","id":1022,"evidence_items":{"accepted_count":2,"rejected_count":1,"submitted_count":4}},{"name":"F317L","id":1028,"evidence_items":{"accepted_count":1,"rejected_count":1,"submitted_count":6}},{"name":"L384M","id":1230,"evidence_items":{"accepted_count":1,"rejected_count":0,"submitted_count":4}},{"name":"G250E","id":1023,"evidence_items":{"accepted_count":3,"rejected_count":0,"submitted_count":12}},{"name":"BCR-ABL F317L","id":241,"evidence_items":{"accepted_count":5,"rejected_count":0,"submitted_count":10}},{"name":"F359V","id":892,"evidence_items":{"accepted_count":3,"rejected_count":0,"submitted_count":10}},{"name":"BCR-ABL","id":1,"evidence_items":{"accepted_count":7,"rejected_count":0,"submitted_count":0}},{"name":"Y253F","id":1026,"evidence_items":{"accepted_count":2,"rejected_count":0,"submitted_count":9}},{"name":"BCR-ABL G398R","id":1233,"evidence_items":{"accepted_count":2,"rejected_count":0,"submitted_count":1}},{"name":"D276G","id":1027,"evidence_items":{"accepted_count":2,"rejected_count":1,"submitted_count":6}},{"name":"M244V","id":1021,"evidence_items":{"accepted_count":1,"rejected_count":1,"submitted_count":10}},{"name":"H396R","id":1030,"evidence_items":{"accepted_count":2,"rejected_count":0,"submitted_count":10}},{"name":"E255V","id":1173,"evidence_items":{"accepted_count":2,"rejected_count":0,"submitted_count":11}},{"name":"BCR-ABL F486S","id":1152,"evidence_items":{"accepted_count":1,"rejected_count":0,"submitted_count":3}},{"name":"F359C","id":1184,"evidence_items":{"accepted_count":1,"rejected_count":0,"submitted_count":5}},{"name":"E292V","id":1183,"evidence_items":{"accepted_count":1,"rejected_count":0,"submitted_count":1}}],"aliases":["ABL1","c-ABL1","v-abl","p150","bcr/abl","ABL","c-ABL","JTK7"],"type":"gene"},{"id":5,"name":"BRAF","entrez_id":673,"description":"BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer.","variants":[{"name":"AMPLIFICATION","id":1269,"evidence_items":{"accepted_count":1,"rejected_count":0,"submitted_count":0}},{"name":"K601E","id":584,"evidence_items":{"accepted_count":1,"rejected_count":0,"submitted_count":1}},{"name":"TRIM24-BRAF","id":287,"evidence_items":{"accepted_count":2,"rejected_count":0,"submitted_count":0}},{"name":"L597Q","id":583,"evidence_items":{"accepted_count":1,"rejected_count":0,"submitted_count":1}},{"name":"D594V","id":580,"evidence_items":{"accepted_count":1,"rejected_count":0,"submitted_count":0}},{"name":"DEL 485-490","id":522,"evidence_items":{"accepted_count":1,"rejected_count":0,"submitted_count":0}},{"name":"WILD TYPE","id":426,"evidence_items":{"accepted_count":1,"rejected_count":0,"submitted_count":0}},{"name":"V600E","id":12,"evidence_items":{"accepted_count":51,"rejected_count":0,"submitted_count":88}},{"name":"V600K","id":563,"evidence_items":{"accepted_count":3,"rejected_count":0,"submitted_count":12}},{"name":"L597S","id":582,"evidence_items":{"accepted_count":2,"rejected_count":0,"submitted_count":0}},{"name":"V600E AMPLIFICATION","id":14,"evidence_items":{"accepted_count":1,"rejected_count":0,"submitted_count":0}},{"name":"G596C","id":694,"evidence_items":{"accepted_count":1,"rejected_count":0,"submitted_count":0}},{"name":"L597R","id":288,"evidence_items":{"accepted_count":2,"rejected_count":0,"submitted_count":0}},{"name":"PPFIBP2-BRAF","id":617,"evidence_items":{"accepted_count":1,"rejected_count":0,"submitted_count":0}},{"name":"D594G","id":611,"evidence_items":{"accepted_count":3,"rejected_count":0,"submitted_count":1}},{"name":"AKAP9-BRAF","id":184,"evidence_items":{"accepted_count":1,"rejected_count":0,"submitted_count":0}},{"name":"L505H","id":658,"evidence_items":{"accepted_count":2,"rejected_count":0,"submitted_count":0}},{"name":"PAPSS1-BRAF","id":286,"evidence_items":{"accepted_count":2,"rejected_count":0,"submitted_count":0}},{"name":"V600E+V600M","id":13,"evidence_items":{"accepted_count":1,"rejected_count":0,"submitted_count":0}},{"name":"V600","id":17,"evidence_items":{"accepted_count":12,"rejected_count":1,"submitted_count":0}},{"name":"KIAA1549-BRAF","id":618,"evidence_items":{"accepted_count":2,"rejected_count":0,"submitted_count":0}},{"name":"V600D","id":11,"evidence_items":{"accepted_count":1,"rejected_count":0,"submitted_count":2}},{"name":"L597V","id":585,"evidence_items":{"accepted_count":1,"rejected_count":0,"submitted_count":0}},{"name":"MUTATION","id":399,"evidence_items":{"accepted_count":4,"rejected_count":0,"submitted_count":0}},{"name":"AGK-BRAF","id":285,"evidence_items":{"accepted_count":2,"rejected_count":0,"submitted_count":0}},{"name":"D594A","id":579,"evidence_items":{"accepted_count":1,"rejected_count":0,"submitted_count":0}},{"name":"BRAF-CUL1","id":656,"evidence_items":{"accepted_count":1,"rejected_count":0,"submitted_count":0}},{"name":"K483M","id":581,"evidence_items":{"accepted_count":1,"rejected_count":0,"submitted_count":0}},{"name":"ZKSCAN1-BRAF","id":657,"evidence_items":{"accepted_count":1,"rejected_count":0,"submitted_count":0}}],"aliases":["BRAF","B-RAF1","B-raf","RAFB1","BRAF1","NS7"],"type":"gene"},{"id":6,"name":"BRCA1","entrez_id":672,"description":"BRCA1 mutations in the germline have become a hallmark for hereditary breast and ovarian cancers. Variants that have been demonstrated to reduce the function of the protein have been shown to increase risk for these cancers, as well as prostate and pancreatic cancer. These findings have been the impetus for the increased popularity of genetic testing of healthy individuals to assess risk. Variant frequencies in 10,000 women over 70 have been released","variants":[{"name":"P968FS","id":477,"evidence_items":{"accepted_count":2,"rejected_count":0,"submitted_count":0}},{"name":"EXPRESSION","id":397,"evidence_items":{"accepted_count":1,"rejected_count":0,"submitted_count":0}},{"name":"Alu insertion","id":709,"evidence_items":{"accepted_count":1,"rejected_count":0,"submitted_count":0}},{"name":"UNDEREXPRESSION","id":403,"evidence_items":{"accepted_count":1,"rejected_count":0,"submitted_count":0}},{"name":"LOSS-OF-FUNCTION","id":131,"evidence_items":{"accepted_count":6,"rejected_count":0,"submitted_count":1}},{"name":"MUTATION","id":185,"evidence_items":{"accepted_count":10,"rejected_count":0,"submitted_count":1}}],"aliases":["PSCP","BRCA1","PPP1R53","PNCA4","IRIS","FANCS","BROVCA1","BRCC1","RNF53","BRCAI"],"type":"gene"},{"id":7,"name":"BRCA2","entrez_id":675,"description":"BRCA2 mutations in the germline have become a hallmark for hereditary breast and ovarian cancers. Variants that have been demonstrated to reduce the function of the protein have been shown to increase risk for these cancers, as well as prostate and pancreatic cancer. These findings have been the impetus for the increased popularity of genetic testing of healthy indivudals to assess risk.","variants":[{"name":"MUTATION","id":186,"evidence_items":{"accepted_count":9,"rejected_count":0,"submitted_count":1}},{"name":"D3095E","id":661,"evidence_items":{"accepted_count":1,"rejected_count":0,"submitted_count":0}},{"name":"TRUNCATING MUTATION","id":708,"evidence_items":{"accepted_count":1,"rejected_count":0,"submitted_count":0}},{"name":"LOSS-OF-FUNCTION","id":132,"evidence_items":{"accepted_count":6,"rejected_count":0,"submitted_count":2}}],"aliases":["BRCA2","FAD1","XRCC11","FAD","PNCA2","FANCD1","GLM3","FANCD","FACD","BROVCA2","BRCC2"],"type":"gene"},{"id":8,"name":"CCND1","entrez_id":595,"description":"Cyclin D has been shown in many cancer types to be misregulated. Well established for their oncogenic properties, the cyclins, and the cyclin-dependent kinases (CDK's) they activate, have been the focus of major research and development efforts over the past decade. The methods by which the cyclins are misregulated are widely variable, ranging from genomic amplification to changes in promoter methylation. While Cyclin D2 has only been found to be significantly deregulated in glioma, Cyclin D1 seems to be a pan-cancer actor. Cyclin D misregulation has been shown to lead to poorer outcomes in a number of studies, but currently there are no FDA-approved targeted therapies.","variants":[{"name":"AMPLIFICATION","id":18,"evidence_items":{"accepted_count":6,"rejected_count":0,"submitted_count":0}},{"name":"EXPRESSION","id":19,"evidence_items":{"accepted_count":2,"rejected_count":0,"submitted_count":0}},{"name":"OVEREXPRESSION","id":20,"evidence_items":{"accepted_count":7,"rejected_count":0,"submitted_count":0}}],"aliases":["CCND1","PRAD1","D11S287E","BCL1","U21B31"],"type":"gene"},{"id":9,"name":"CCND2","entrez_id":894,"description":"Cyclin D has been shown in many cancer types to be misregulated. Well established for their oncogenic properties, the cyclins and the cyclin-dependent kinases (CDK's) they activate have been the focus of major research and development efforts over the past decade. The methods by which the cyclins are misregulated are widely variable, ranging from genomic amplification to changes in promoter methylation. While Cyclin D2 has only been found to be significantly deregulated in glioma, Cyclin D1 in particular seems to be a pan-cancer actor. Cyclin D misregulation has been shown to lead to poorer outcomes in a number of studies, and currently there are no FDA-approved targeted therapies.","variants":[{"name":"OVEREXPRESSION","id":21,"evidence_items":{"accepted_count":4,"rejected_count":0,"submitted_count":0}},{"name":"PROMOTER DEMETHYLATION","id":22,"evidence_items":{"accepted_count":1,"rejected_count":0,"submitted_count":0}}],"aliases":["CCND2","MPPH3","KIAK0002"],"type":"gene"},{"id":10,"name":"CCND3","entrez_id":896,"description":"Cyclin D has been shown in many cancer types to be misregulated. Well established for their oncogenic properties, the cyclins and the cyclin-dependent kinases (CDK's) they activate have been the focus of major research and development efforts over the past decade. The methods by which the cyclins are misregulated are widely variable, ranging from genomic amplification to changes in promoter methylation. Cyclin D3 loss has been reported in T-ALL, a seemingly unique trend when compared to the amplifcations and overexpressions of the other cyclin D's. In a mouse study, the targeted therapeutic palbociclib significantly increased the median survival of the cyclin D3 knockouts.","variants":[{"name":"LOSS","id":23,"evidence_items":{"accepted_count":1,"rejected_count":0,"submitted_count":0}}],"aliases":["CCND3"],"type":"gene"},{"id":11,"name":"CCNE1","entrez_id":898,"description":"Cyclin E, while currenly not as widely implicated as its cyclin D counterparts, has been implicated in various carcinomas, including breast, gastric, stomach and colorectal. High levels of cyclin E, either by gene amplification or overexpression, have been shown to lead to poorer prognosis in gastic carcinoma, and these measurements are correlated with later stage disease. In lung cancer, neoplastic cells with higher levels of the cyclin E/CDK2 complex are more radiosensitive than their more lowly expressed counterparts.","variants":[{"name":"OVEREXPRESSION","id":24,"evidence_items":{"accepted_count":4,"rejected_count":0,"submitted_count":0}},{"name":"AMPLIFICATION","id":187,"evidence_items":{"accepted_count":3,"rejected_count":0,"submitted_count":0}}],"aliases":["CCNE1","pCCNE1","CCNE"],"type":"gene"},{"id":12,"name":"CDK6","entrez_id":1021,"description":"CDK6, along with its partner CDK4, are key players in cell cycle progression. The complex has been implicated in a number of cancer types, and is the focus of therapeutic research and development. One targeted therapy for CDK inhibition is palbociclib, which may slow the growth of advanced stage breast cancers. It has also been shown, in mouse, that CDK inhibition may sensitize mutant PIK3CA tumors to PI3K inhibitors.","variants":[{"name":"OVEREXPRESSION","id":602,"evidence_items":{"accepted_count":2,"rejected_count":0,"submitted_count":0}}],"aliases":["CDK6","PLSTIRE","MCPH12"],"type":"gene"},{"id":13,"name":"CDK4","entrez_id":1019,"description":"CDK4, along with its partner CDK6, are key players in cell cycle progression. The complex has been implicated in a number of cancer types, and is the focus of therapeutic research and development. One targeted therapy for CDK inhibition is palbociclib, which may slow the growth of advanced stage breast cancers. It has also been shown, in mouse, that CDK inhibition may sensitize mutant PIK3CA tumors to PI3K inhibitors.","variants":[{"name":"R24C","id":556,"evidence_items":{"accepted_count":1,"rejected_count":0,"submitted_count":0}},{"name":"EXPRESSION","id":25,"evidence_items":{"accepted_count":2,"rejected_count":1,"submitted_count":0}},{"name":"AMPLIFICATION","id":553,"evidence_items":{"accepted_count":2,"rejected_count":0,"submitted_count":0}}],"aliases":["CDK4","CMM3","PSK-J3"],"type":"gene"},{"id":14,"name":"CDKN2A","entrez_id":1029,"description":"CDKN2A loss has been shown to be a significant event in a number of cancer types. While no targeted therapeutic has been engaged in clinical trials, the prognostic impact has been studied by a number of meta-analyses. In majority of cases CDKN2A is inactivated by homozygous deletions. One of the mechanisms by which loss of CDKN2A can occur is by hypermethylation of the promoter region for the gene. However, the prognostic impact of promoter hypermethylation has been relatively ambiguous. Many studies have suggesting poorer prognostic outcome for patients with hypermethylation in colorectal, liver, and younger lung cancer patients. This being said, there is still research to be done before this becomes a widely-accepted prognostic indicator.\nAdditionally, CDKN2A (p16) expression is a surrogate marker for HPV infection. As such, CDKN2A expression is prognostic in Oropharyngeal and probably also non-oropharyngeal head and neck squamous cell carcinomas.","variants":[{"name":"PROMOTER HYPERMETHYLATION","id":27,"evidence_items":{"accepted_count":2,"rejected_count":0,"submitted_count":0}},{"name":"p16 EXPRESSION","id":272,"evidence_items":{"accepted_count":10,"rejected_count":0,"submitted_count":1}},{"name":"RS3814960","id":641,"evidence_items":{"accepted_count":1,"rejected_count":0,"submitted_count":0}},{"name":"LOSS","id":554,"evidence_items":{"accepted_count":7,"rejected_count":0,"submitted_count":1}}],"aliases":["P16-INK4A","INK4A","P14ARF","P16","P19ARF","CDKN2A","P19","P16INK4","P16INK4A","MTS1","MLM","MTS-1","CMM2","ARF","INK4","CDKN2","CDK4I","TP16","P14"],"type":"gene"},{"id":15,"name":"CEBPA","entrez_id":1050,"description":"'AML with mutated CEBPA' is a provisional entity in the WHO classification of acute myeloid leukemia (AML) and is recommended to be tested for in patients with AML. CEBPA mutations are particularly associated with cytogenetically normal AML (CN-AML). CEBPA is an intronless gene that is required for granulocyte formation in mice. N-terminal nonsense mutations result in a dominant negative C/EBP-alpha protein while C-terminal mutations reduce the DNA-binding potential of this transcription factor. CEBPA mutations are associated with a favorable prognosis, however, NPM1 and FLT3 mutations should also be assessed in CN-AML patients as concurrent mutations may have prognostic implications.","variants":[{"name":"MUTATION","id":29,"evidence_items":{"accepted_count":6,"rejected_count":0,"submitted_count":0}},{"name":"BIALLELIC INACTIVATION","id":594,"evidence_items":{"accepted_count":1,"rejected_count":0,"submitted_count":0}},{"name":"N-TERMINAL FRAME SHIFT","id":28,"evidence_items":{"accepted_count":2,"rejected_count":0,"submitted_count":0}}],"aliases":["CEBPA","CEBP","C/EBP-alpha"],"type":"gene"},{"id":17,"name":"PRKACA","entrez_id":5566,"description":"PRKACA has been studied in breast cancer and has been found to mediate resistance to HER2 targeted therapies. It has also been found to contain a mutation hotspot that contributes to neoplastic behavior in neuroendocrine cancers. In hepatocellular fibrolamellar carcinoma (FL-HCC), the fusion DNAJB1 to PRKACA is suggested to be a diagnostic marker for this rare subtype of HCC. In one study, this fusion was observed in 15/15 FL-HCC cases examined and functional studies found that the fusion retained kinase activity.","variants":[{"name":"DNAJB1-PRKACA","id":31,"evidence_items":{"accepted_count":4,"rejected_count":0,"submitted_count":0}}],"aliases":["PRKACA","PPNAD4","PKACA"],"type":"gene"},{"id":18,"name":"DNMT3A","entrez_id":1788,"description":"DNMT3A is one of several epigenetic modifiers identified as recurrently mutated in acute myeloid leukemia (AML). DNMT3A mutations are associated with cytogenetically normal AML. In vitro experiments indicate that the R882H mutation acts in a dominant negative manner to disrupt the de novo methyltransferase activity of wildtype homotetramers. AML patient bone marrow harboring R882 mutations were similarly demonstrated to be hypomethylated compared to patients with wildtype DNMT3A. These studies also indicated that non-R882 DNMT3A mutations may act in a functionally distinct manner from R882 mutations. Alternative mechanisms indicate independent prognostic outcomes and treatment protocols may need to be considered for these two classes of DNMT3A mutations.","variants":[{"name":"MUTATION","id":189,"evidence_items":{"accepted_count":7,"rejected_count":0,"submitted_count":0}},{"name":"R882","id":32,"evidence_items":{"accepted_count":28,"rejected_count":0,"submitted_count":0}}],"aliases":["DNMT3A2","DNMT3A","TBRS","M.HsaIIIA"],"type":"gene"},{"id":19,"name":"EGFR","entrez_id":1956,"description":"EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in treatment of non-small cell lung cancer. \nOverproduction of ligands is another possible mechanism of activation of EGFR. ERBB ligands include EGF, TGF-a, AREG, EPG, BTC, HB-EGF, EPR and NRG1-4 (for detailed information please refer to the respective ligand section). In ligand-activated cancers, Cetuximab appears to be more effective than tyrosine-kinase inhibitors (Arteaga et. al.).","variants":[{"name":"L838P","id":1457,"evidence_items":{"accepted_count":1,"rejected_count":0,"submitted_count":0}},{"name":"T847I","id":1463,"evidence_items":{"accepted_count":1,"rejected_count":0,"submitted_count":0}},{"name":"RARE EX 18-21 MUT","id":1863,"evidence_items":{"accepted_count":2,"rejected_count":0,"submitted_count":0}},{"name":"L858R","id":33,"evidence_items":{"accepted_count":20,"rejected_count":0,"submitted_count":23}},{"name":"R108K","id":994,"evidence_items":{"accepted_count":1,"rejected_count":0,"submitted_count":0}},{"name":"D761Y","id":712,"evidence_items":{"accepted_count":1,"rejected_count":0,"submitted_count":0}},{"name":"EXON 20 INSERTION","id":726,"evidence_items":{"accepted_count":2,"rejected_count":0,"submitted_count":2}},{"name":"L747_P753delinsS","id":1012,"evidence_items":{"accepted_count":1,"rejected_count":0,"submitted_count":13}},{"name":"P753S","id":460,"evidence_items":{"accepted_count":1,"rejected_count":0,"submitted_count":0}},{"name":"S492R","id":453,"evidence_items":{"accepted_count":4,"rejected_count":0,"submitted_count":0}},{"name":"AMPLIFICATION","id":190,"evidence_items":{"accepted_count":9,"rejected_count":0,"submitted_count":0}},{"name":"E746G","id":724,"evidence_items":{"accepted_count":1,"rejected_count":0,"submitted_count":0}},{"name":"EXON 19 DELETION","id":133,"evidence_items":{"accepted_count":15,"rejected_count":0,"submitted_count":0}},{"name":"L861Q","id":1020,"evidence_items":{"accepted_count":2,"rejected_count":0,"submitted_count":2}},{"name":"K806E","id":1895,"evidence_items":{"accepted_count":1,"rejected_count":0,"submitted_count":0}},{"name":"EXON 18 OVEREXPRESSION","id":375,"evidence_items":{"accepted_count":1,"rejected_count":0,"submitted_count":0}},{"name":"L861R","id":1477,"evidence_items":{"accepted_count":1,"rejected_count":0,"submitted_count":1}},{"name":"V851I","id":1466,"evidence_items":{"accepted_count":1,"rejected_count":0,"submitted_count":0}},{"name":"V774M","id":1894,"evidence_items":{"accepted_count":1,"rejected_count":0,"submitted_count":0}},{"name":"V774A","id":1892,"evidence_items":{"accepted_count":1,"rejected_count":0,"submitted_count":0}},{"name":"G724S","id":317,"evidence_items":{"accepted_count":1,"rejected_count":0,"submitted_count":0}},{"name":"N826S","id":1188,"evidence_items":{"accepted_count":1,"rejected_count":0,"submitted_count":0}},{"name":"EXPRESSION","id":354,"evidence_items":{"accepted_count":6,"rejected_count":0,"submitted_count":1}},{"name":"K467T","id":455,"evidence_items":{"accepted_count":2,"rejected_count":0,"submitted_count":0}},{"name":"G719S","id":134,"evidence_items":{"accepted_count":4,"rejected_count":0,"submitted_count":3}},{"name":"K757R","id":723,"evidence_items":{"accepted_count":1,"rejected_count":0,"submitted_count":0}},{"name":"L747P","id":1891,"evidence_items":{"accepted_count":1,"rejected_count":0,"submitted_count":0}},{"name":"G719D","id":1420,"evidence_items":{"accepted_count":1,"rejected_count":0,"submitted_count":0}},{"name":"A864T","id":1187,"evidence_items":{"accepted_count":1,"rejected_count":0,"submitted_count":0}},{"name":"R451C","id":454,"evidence_items":{"accepted_count":1,"rejected_count":0,"submitted_count":0}},{"name":"G719A","id":999,"evidence_items":{"accepted_count":1,"rejected_count":0,"submitted_count":4}},{"name":"V834I","id":1897,"evidence_items":{"accepted_count":1,"rejected_count":0,"submitted_count":0}},{"name":"S720","id":720,"evidence_items":{"accepted_count":1,"rejected_count":0,"submitted_count":0}},{"name":"G719","id":718,"evidence_items":{"accepted_count":2,"rejected_count":0,"submitted_count":0}},{"name":"V742A","id":1001,"evidence_items":{"accepted_count":1,"rejected_count":0,"submitted_count":2}},{"name":"OVEREXPRESSION","id":193,"evidence_items":{"accepted_count":8,"rejected_count":2,"submitted_count":2}},{"name":"EXON 4 DELETION","id":252,"evidence_items":{"accepted_count":1,"rejected_count":0,"submitted_count":0}},{"name":"T263P","id":995,"evidence_items":{"accepted_count":1,"rejected_count":0,"submitted_count":0}},{"name":"V769_770insASV","id":736,"evidence_items":{"accepted_count":1,"rejected_count":0,"submitted_count":1}},{"name":"R776C","id":1181,"evidence_items":{"accepted_count":1,"rejected_count":0,"submitted_count":1}},{"name":"A289V","id":996,"evidence_items":{"accepted_count":1,"rejected_count":0,"submitted_count":0}},{"name":"G465R","id":443,"evidence_items":{"accepted_count":2,"rejected_count":0,"submitted_count":0}},{"name":"Ex19 del L858R","id":1854,"evidence_items":{"accepted_count":3,"rejected_count":0,"submitted_count":0}},{"name":"L861","id":1866,"evidence_items":{"accepted_count":1,"rejected_count":0,"submitted_count":0}},{"name":"L838V","id":1018,"evidence_items":{"accepted_count":1,"rejected_count":0,"submitted_count":0}},{"name":"C797S","id":415,"evidence_items":{"accepted_count":2,"rejected_count":0,"submitted_count":1}},{"name":"COPY NUMBER VARIATION","id":191,"evidence_items":{"accepted_count":1,"rejected_count":0,"submitted_count":0}},{"name":"VIII","id":312,"evidence_items":{"accepted_count":7,"rejected_count":0,"submitted_count":0}},{"name":"S768I","id":562,"evidence_items":{"accepted_count":5,"rejected_count":0,"submitted_count":4}},{"name":"Y1092 PHOSPHORYLATION","id":390,"evidence_items":{"accepted_count":1,"rejected_count":0,"submitted_count":0}},{"name":"N826Y","id":1896,"evidence_items":{"accepted_count":1,"rejected_count":0,"submitted_count":0}},{"name":"N842S","id":1899,"evidence_items":{"accepted_count":1,"rejected_count":0,"submitted_count":0}},{"name":"MUTATION","id":442,"evidence_items":{"accepted_count":8,"rejected_count":1,"submitted_count":0}},{"name":"T790M","id":34,"evidence_items":{"accepted_count":30,"rejected_count":2,"submitted_count":8}}],"aliases":["ERBB","ERBB1","mENA","EGFR","NISBD2","PIG61","HER1"],"type":"gene"},{"id":20,"name":"ERBB2","entrez_id":2064,"description":"ERBB2, commonly referred to as HER2, is amplified and/or overexpressed in 20-30% of invasive breast carcinomas. HER2-positive breast cancer is treated in a separate manner from other subtypes of breast cancer. Metastatic HER2-positive breast cancer is now commonly treated with HER2-targeted therapy. Apart from being amplified/overexpressed, ERBB2 activating mutations have been shown to have clinical importance in HER2-negative breast cancer. These mutations have shown sensitivity to the tyrosine kinase inhibitor neratinib, and highlight the importance of clinical sequencing efforts in treating breast cancer.","variants":[{"name":"G309A","id":38,"evidence_items":{"accepted_count":1,"rejected_count":0,"submitted_count":0}},{"name":"D769H","id":35,"evidence_items":{"accepted_count":1,"rejected_count":0,"submitted_count":0}},{"name":"T862A","id":871,"evidence_items":{"accepted_count":1,"rejected_count":0,"submitted_count":0}},{"name":"AMPLIFICATION","id":306,"evidence_items":{"accepted_count":52,"rejected_count":0,"submitted_count":0}},{"name":"R678Q","id":42,"evidence_items":{"accepted_count":1,"rejected_count":0,"submitted_count":0}},{"name":"N857S","id":873,"evidence_items":{"accepted_count":1,"rejected_count":0,"submitted_count":0}},{"name":"H878Y","id":874,"evidence_items":{"accepted_count":1,"rejected_count":0,"submitted_count":0}},{"name":"V842I","id":45,"evidence_items":{"accepted_count":2,"rejected_count":0,"submitted_count":1}},{"name":"Y772_A775DUP","id":815,"evidence_items":{"accepted_count":2,"rejected_count":0,"submitted_count":1}},{"name":"MUTATION","id":666,"evidence_items":{"accepted_count":1,"rejected_count":0,"submitted_count":1}},{"name":"M774INSAYVM","id":414,"evidence_items":{"accepted_count":6,"rejected_count":0,"submitted_count":0}},{"name":"L866M","id":496,"evidence_items":{"accepted_count":1,"rejected_count":0,"submitted_count":1}},{"name":"V773A","id":872,"evidence_items":{"accepted_count":1,"rejected_count":0,"submitted_count":0}},{"name":"G778_P780DUP","id":817,"evidence_items":{"accepted_count":2,"rejected_count":0,"submitted_count":0}},{"name":"L755W","id":40,"evidence_items":{"accepted_count":1,"rejected_count":0,"submitted_count":0}},{"name":"R896C","id":43,"evidence_items":{"accepted_count":1,"rejected_count":0,"submitted_count":0}},{"name":"G776L","id":816,"evidence_items":{"accepted_count":1,"rejected_count":0,"submitted_count":0}},{"name":"P780INS","id":41,"evidence_items":{"accepted_count":2,"rejected_count":0,"submitted_count":0}},{"name":"V777L","id":44,"evidence_items":{"accepted_count":2,"rejected_count":0,"submitted_count":2}},{"name":"D769Y","id":36,"evidence_items":{"accepted_count":1,"rejected_count":0,"submitted_count":0}},{"name":"S310F/Y","id":497,"evidence_items":{"accepted_count":1,"rejected_count":0,"submitted_count":1}},{"name":"OVEREXPRESSION","id":875,"evidence_items":{"accepted_count":1,"rejected_count":0,"submitted_count":1}},{"name":"KINASE DOMAIN MUTATION","id":413,"evidence_items":{"accepted_count":2,"rejected_count":0,"submitted_count":0}},{"name":"SERUM LEVELS","id":416,"evidence_items":{"accepted_count":2,"rejected_count":0,"submitted_count":0}},{"name":"M774DELINSWLV","id":818,"evidence_items":{"accepted_count":1,"rejected_count":0,"submitted_count":0}},{"name":"L755S","id":39,"evidence_items":{"accepted_count":3,"rejected_count":0,"submitted_count":3}},{"name":"DEL 755-759","id":37,"evidence_items":{"accepted_count":1,"rejected_count":0,"submitted_count":0}}],"aliases":["HER-2/neu","ERBB2","HER-2","CD340","HER2","NEU","NGL","TKR1","MLN 19"],"type":"gene"},{"id":21,"name":"ESR1","entrez_id":2099,"description":"ESR1 has been a focus in breast cancer for quite some time, but is also clinically relevant in endometrial, ovarian and other cancer types. The identification of ER-positive breast cancers that are resistant to hormone therapy have inspired clinical sequencing efforts to shed light on the mechanisms of this resistance. A number of mutations in the ligand binding domain of ESR1 have been implicated in hormone resistance and anti-estrogen therapies. These observations have spurred efforts to develop therapeutics that stimulate ESR1 protein degradation (e.g. Fulvestrant), rather than acting as a small molecule antagonist. These agents are currently in clinical trials and have seen some success.","variants":[{"name":"Y537S","id":50,"evidence_items":{"accepted_count":2,"rejected_count":0,"submitted_count":2}},{"name":"OVEREXPRESSION","id":607,"evidence_items":{"accepted_count":1,"rejected_count":0,"submitted_count":0}},{"name":"Y537N","id":49,"evidence_items":{"accepted_count":2,"rejected_count":0,"submitted_count":2}},{"name":"L536Q","id":46,"evidence_items":{"accepted_count":2,"rejected_count":0,"submitted_count":0}},{"name":"Y537C","id":48,"evidence_items":{"accepted_count":2,"rejected_count":0,"submitted_count":1}},{"name":"S463P","id":692,"evidence_items":{"accepted_count":1,"rejected_count":0,"submitted_count":1}},{"name":"D538G","id":47,"evidence_items":{"accepted_count":3,"rejected_count":0,"submitted_count":1}}],"aliases":["ESR1","ESRA","ESR","ESTRR","ER","NR3A1","Era"],"type":"gene"},{"id":22,"name":"FGFR2","entrez_id":2263,"description":"The FGFR proteins are involved in a wide array of pathways known to play a signficant role in cancer. Activation of these receptors can lead to activation of the RAS-MAPK pathway and the PI3K-AKT pathway, among others. The mechanisms by which FGFR can be misregulated vary between cancers. Amplification of the receptors has been observed in lung and breast cancers, coding mutations and deletions have been seen in many cancers, and more recently, FGFR fusions that lead to pathway actiation have been demonstrated to have oncogenic potential across multiple cancer types. The targeted therapeutics ponatinib, dovitinib and pazopanib have seen success in treating over-active FGFR signalling, prompting use of diagnostic sequencing targeting the FGFR genes, especially in lung cancer patients.","variants":[{"name":"FGFR2-AHCYL1","id":783,"evidence_items":{"accepted_count":2,"rejected_count":0,"submitted_count":0}},{"name":"MUTATION","id":511,"evidence_items":{"accepted_count":2,"rejected_count":0,"submitted_count":0}},{"name":"N550K","id":545,"evidence_items":{"accepted_count":1,"rejected_count":0,"submitted_count":0}},{"name":"FGFR2-TACC3","id":54,"evidence_items":{"accepted_count":1,"rejected_count":0,"submitted_count":0}},{"name":"FGFR2-BICC1","id":782,"evidence_items":{"accepted_count":4,"rejected_count":0,"submitted_count":0}},{"name":"FGFR2-MGEA5","id":52,"evidence_items":{"accepted_count":1,"rejected_count":0,"submitted_count":0}},{"name":"FUSION","id":828,"evidence_items":{"accepted_count":2,"rejected_count":0,"submitted_count":0}},{"name":"AMPLIFICATION","id":629,"evidence_items":{"accepted_count":2,"rejected_count":0,"submitted_count":0}}],"aliases":["JWS","TK25","FGFR2","K-SAM","TK14","KGFR","BFR-1","CFD1","CEK3","CD332","ECT1","BEK","BBDS"],"type":"gene"},{"id":23,"name":"FGFR3","entrez_id":2261,"description":"The FGFR proteins are involved in a wide array of pathways known to play a signficant role in cancer. Activation of these receptors can lead to activation of the RAS-MAPK pathway and the PI3K-AKT pathway, among others. The mechanisms by which FGFR can be misregulated vary between cancers. Amplification of the receptors has been observed in lung and breast cancers, coding mutations and deletions have been seen in many cancers, and more recently, FGFR fusions that lead to pathway actiation have been demonstrated to have oncogenic potential across multiple cancer types. The targeted therapeutics ponatinib, dovitinib and pazopanib have seen success in treating over-active FGFR signalling, prompting use of diagnostic sequencing targeting the FGFR genes, especially in lung cancer patients.","variants":[{"name":"MUTATION","id":827,"evidence_items":{"accepted_count":1,"rejected_count":0,"submitted_count":0}},{"name":"FGFR3-BAIAP2L1","id":53,"evidence_items":{"accepted_count":1,"rejected_count":0,"submitted_count":0}},{"name":"FGFR3-TACC3","id":830,"evidence_items":{"accepted_count":1,"rejected_count":1,"submitted_count":0}},{"name":"Y375C","id":196,"evidence_items":{"accepted_count":1,"rejected_count":0,"submitted_count":0}},{"name":"EXPRESSION","id":325,"evidence_items":{"accepted_count":1,"rejected_count":0,"submitted_count":0}},{"name":"S249C","id":628,"evidence_items":{"accepted_count":1,"rejected_count":0,"submitted_count":1}}],"aliases":["CD333","CEK2","FGFR3","HSFGFR3EX","JTK4","ACH"],"type":"gene"},{"id":24,"name":"FLT3","entrez_id":2322,"description":"FLT3 is an important cytokine receptor involved in normal hematopoiesis. Mutations in this gene are common in acute myeloid leukemia (AML) and screening for mutations in this gene has been recommended by the World Health Organization in patients with AML, particularly in cases of cytogenetically normal AML (CN-AML). FLT3 mutations commonly co-occur with mutations such as NPM1 that are associated with CN-AML and likely modulate prognostic impact. While FLT3-ITD mutations have been associated with poorer prognosis in AML, the prognostic impact of FLT3-TKD mutations are still up for debate.","variants":[{"name":"D835V","id":1302,"evidence_items":{"accepted_count":6,"rejected_count":0,"submitted_count":6}},{"name":"ITD","id":55,"evidence_items":{"accepted_count":27,"rejected_count":0,"submitted_count":0}},{"name":"D835H","id":612,"evidence_items":{"accepted_count":1,"rejected_count":0,"submitted_count":2}},{"name":"MUTATION","id":519,"evidence_items":{"accepted_count":2,"rejected_count":0,"submitted_count":2}},{"name":"T227M","id":540,"evidence_items":{"accepted_count":1,"rejected_count":0,"submitted_count":0}},{"name":"D835H/Y","id":613,"evidence_items":{"accepted_count":1,"rejected_count":0,"submitted_count":0}},{"name":"OVEREXPRESSION","id":603,"evidence_items":{"accepted_count":1,"rejected_count":0,"submitted_count":0}},{"name":"D835","id":437,"evidence_items":{"accepted_count":4,"rejected_count":0,"submitted_count":3}},{"name":"TKD MUTATION","id":56,"evidence_items":{"accepted_count":7,"rejected_count":0,"submitted_count":0}}],"aliases":["FLK-2","FLT3","STK1","FLK2","CD135"],"type":"gene"},{"id":25,"name":"GATA2","entrez_id":2624,"description":"GATA2 is a transcription factor involved in stem cell maintenance with key roles in hematopoietic development. GATA2 mutations are associated with a variety of inherited and acquired immune disorders including myelodysplastic syndrome and acute myeloid leukemia. In addition to a role in hematopoiesis, the maintenance GATA2 expression has been implicated as a requirement in KRAS-driven non-small cell lung cancer. Preclinical models have indicated therapeutic benefit from targeting GATA2-mediated pathways in the context of KRAS-driven NSCLC.","variants":[{"name":"EXPRESSION","id":57,"evidence_items":{"accepted_count":1,"rejected_count":0,"submitted_count":0}}],"aliases":["NFE1B","MONOMAC","IMD21","DCML","GATA2"],"type":"gene"},{"id":26,"name":"IDH1","entrez_id":3417,"description":"IDH1 mutations have been observed in a number of cancer types, including sarcomas, hematologic malignancies, colon cancer and brain cancer. Mutations in the two isocitrate dehydrogenase enzymes involved in cytoplasmic (IDH1) and mitochondrial (IDH2) conversion of alpha-ketoglutarate to D-2-hydroxyglutarate have been described as mutually exclusive in many of these cancer types. The most frequent mutations involve R132 (IDH1) and R172 (IDH2) involve the active site and result in neomorphic enzyme activity. The implications of mutations in this gene vary greatly by cancer type. In myelodysplastic syndromes and acute myeloid leukemia (AML), IDH1 mutations have been associated with worse outcome, shorter overall survival, and normal karyotype. However, in glioblastoma and astrocytoma, patients with IDH1 mutations have shown better overall survival than patients with wild-type IDH1. Unlike the association with cytogenetically normal AML, in glioblastoma, IDH1 mutations have been associated with specific cytogenetic abnormalities, 1p and 19q deletions.","variants":[{"name":"R132C","id":59,"evidence_items":{"accepted_count":9,"rejected_count":2,"submitted_count":0}},{"name":"MUTATION","id":645,"evidence_items":{"accepted_count":2,"rejected_count":0,"submitted_count":0}},{"name":"R132H","id":420,"evidence_items":{"accepted_count":1,"rejected_count":0,"submitted_count":4}},{"name":"R132L","id":880,"evidence_items":{"accepted_count":1,"rejected_count":1,"submitted_count":4}},{"name":"R132S","id":928,"evidence_items":{"accepted_count":1,"rejected_count":1,"submitted_count":4}},{"name":"R132","id":58,"evidence_items":{"accepted_count":8,"rejected_count":0,"submitted_count":0}}],"aliases":["HEL-216","IDP","IDH","IDH1","PICD","IDPC","IDCD","HEL-S-26"],"type":"gene"}]}